AbbVie secured exclusive rights to IGI Therapeutics’ early-stage trispecific antibody ISB-2001 targeting BCMA, CD38, and CD3 for multiple myeloma and autoimmune indications in a $700 million upfront deal with potential milestones exceeding $1.2 billion. The antibody has received Orphan Drug and Fast Track designations, validating its promise. Preliminary Phase 1 data revealed a 79% response rate with manageable safety. AbbVie plans to further develop ISB-2001 and explore its utility across oncology and autoimmune diseases, enhancing its immuno-oncology pipeline.